Clinical Trial

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with NECTIN4-amplified recurrent, unresectable, or metastatic breast cancer who have received prior therapy (see inclusion criteria below). The study will comprise of 2 cohorts. Cohort A will include participants with hormone receptor positive/ human epidermal growth factor receptor 2 negative \[HR+/HER2-\] breast cancer, whereas Cohort B will include participants with triple-negative breast cancer (TNBC).
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-16
notable Trial sites reduced: 39 -> 18 locations 2026-04-16
Trial Details
NCT Number NCT06840483
Lead Sponsor BicycleTx Limited
Conditions Breast Cancer
Enrollment 66 participants
Start Date 2025-03-03
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-15